TG Therapeutics, Inc. (TGTX) - Form 8-K Summary
Business Context and Reporting Period
TG Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on February 26, 2026. The filing serves to announce the results of operations for the three and twelve months ended December 31, 2025. The company's common stock trades on the Nasdaq Capital Market under the symbol TGTX.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
Specific material changes versus the prior comparable period are not detailed in the cover page of this filing. The report indicates that the company has issued a press release containing these operational results, but the text of that release is not present in the source data.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 26, 2026) for actual financial figures for the three and twelve months ended December 31, 2025.
- Verify the specific revenue and net loss figures reported in the press release to assess year-over-year performance.
- Check the press release for updates on clinical trial progress or regulatory milestones, which are typical drivers for TG Therapeutics.
- Confirm cash position and burn rate details from the full press release to evaluate liquidity runway.